Fosun International (HK:0656) has released an update.
Fosun International’s subsidiary, Fosun New Medicine, has entered into a merger agreement with Henlius, which will result in Henlius being absorbed by the Offeror. The transaction is classified as a discloseable event under the Listing Rules, meaning it’s significant but below the threshold for a major transaction. Upon completion, the merger will see the Offeror assume all of Henlius’s assets, liabilities, and obligations.
For further insights into HK:0656 stock, check out TipRanks’ Stock Analysis page.
